insights_auto
Why is CVM up ၇.၅၆%?
Dive Deeperchevron_right
CVM:NYSEAMERICAN
CEL-SCI Corp
၁.၂၈ US$
arrow_upward
+၇.၅၆%(+၀.၀၉၀) 1D
၁.၄၀ US$
arrow_upward
+၉.၃၈% (+၀.၁၂)todayPre-market
Closed: နို ၁၃, GMT-၅ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CVM...
Open
၁.၁၉ US$
High
၁.၂၈ US$
Low
၁.၁၅ US$
Mkt. cap
၂.၂၅ ကုဋေ
Avg. vol.
၁.၉၈ သိန်း
Volume
၂.၂၃ သောင်း
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
Open
၁.၁၉ US$
High
၁.၂၈ US$
Low
၁.၁၅ US$
Mkt. cap
၂.၂၅ ကုဋေ
Avg. vol.
၁.၉၈ သိန်း
Volume
၂.၂၃ သောင်း
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
News stories
From web sources and news partners
Reuters
·
ပြီးခဲ့သည့် ၁ နာရီ
S&P 500, Nasdaq futures slide as Nvidia earnings, Anthropic debut loom
Business Insider
·
ပြီးခဲ့သည့် ၁ နာရီ
A veteran strategist sees a split in the stock market leading to a 15% drop in the S&P 500
Investing.com
·
ပြီးခဲ့သည့် ၃ နာရီ
Morgan Stanley raises S&P 500 target on earnings growth, lower oil and AI adoption
Traders Union
·
ပြီးခဲ့သည့် ၁ နာရီ
S&P 500 remained close to all-time highs after Nasdaq's drop, Dario Perkins notes
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees၄၃
Foundedမတ် ၁၉၈၃
Headquartersဗီယင်နာ, ဗာဂျီးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websitecel-sci.com